Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Targeted agents and combinations in ovarian cancer: where are we now?

McLachlan J, Lima JP, Dumas L, Banerjee S.

Expert Rev Anticancer Ther. 2016;16(4):441-54. doi: 10.1586/14737140.2016.1162101. Review.

PMID:
26942837
2.

Targeted therapy of ovarian cancer including immune check point inhibitor.

Kim JY, Cho CH, Song HS.

Korean J Intern Med. 2017 Sep;32(5):798-804. doi: 10.3904/kjim.2017.008. Epub 2017 Aug 22. Review.

3.

Targeted agents in ovarian cancer.

Kristedja TS, Morgan RJ, Cristea M.

Womens Health (Lond). 2010 Sep;6(5):679-94. doi: 10.2217/whe.10.48. Review.

PMID:
20887168
4.

PARP inhibitors in ovarian and other cancers.

Plummer R.

Clin Adv Hematol Oncol. 2015 May;13(5):285-7. No abstract available.

PMID:
26352770
5.

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S.

Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Review.

PMID:
25573350
6.

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.

Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E.

Int J Mol Sci. 2017 Jan 20;18(1). pii: E210. doi: 10.3390/ijms18010210. Review.

7.

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.

Sui H, Shi C, Yan Z, Li H.

Drug Des Devel Ther. 2015 Jun 22;9:3183-90. doi: 10.2147/DDDT.S82035. eCollection 2015.

8.

Targeted Therapies for Ovarian Cancer.

Grunewald T, Ledermann JA.

Best Pract Res Clin Obstet Gynaecol. 2017 May;41:139-152. doi: 10.1016/j.bpobgyn.2016.12.001. Epub 2016 Dec 8. Review.

PMID:
28111228
9.

Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).

Shigetomi H, Higashiura Y, Kajihara H, Kobayashi H.

Oncol Rep. 2012 Aug;28(2):395-408. doi: 10.3892/or.2012.1833. Epub 2012 May 25. Review.

PMID:
22641286
10.

Personalized ovarian cancer treatment.

Rodriguez AO.

Curr Opin Obstet Gynecol. 2012 Feb;24(1):1-2. doi: 10.1097/GCO.0b013e32834fb0a8. No abstract available.

PMID:
22193244
11.

New developments in the treatment of ovarian cancer--future perspectives.

Lopez J, Banerjee S, Kaye SB.

Ann Oncol. 2013 Dec;24 Suppl 10:x69-x76. doi: 10.1093/annonc/mdt475. Review.

12.

Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.

Lum C, Steer CB.

Drugs Aging. 2017 Nov;34(11):821-831. doi: 10.1007/s40266-017-0495-1. Review.

PMID:
29086349
13.

Clinical trials and future potential of targeted therapy for ovarian cancer.

Itamochi H, Kigawa J.

Int J Clin Oncol. 2012 Oct;17(5):430-40. doi: 10.1007/s10147-012-0459-8. Epub 2012 Aug 28. Review.

PMID:
22926640
14.

Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.

Crafton SM, Salani R.

Clin Ther. 2016 Mar;38(3):449-58. doi: 10.1016/j.clinthera.2016.02.007. Epub 2016 Feb 28. Review.

PMID:
26926322
15.

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.

Tewari KS, Eskander RN, Monk BJ.

Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi: 10.1158/1078-0432.CCR-15-0088. Epub 2015 Jul 13. Review.

16.

Novel therapies, including enzastaurin, in the treatment of ovarian cancer.

Vergote I.

Expert Opin Investig Drugs. 2014 May;23(5):579-98. doi: 10.1517/13543784.2014.900542. Epub 2014 Mar 22. Review.

PMID:
24654681
17.

[Molecular Mechanisms of Carcinogenesis of Epithelial Ovarian Cancers].

Müllerová Z, Müller T, Křivánková K, Vojtěšek B, Müller P.

Klin Onkol. Fall 2016;29 Suppl 4(Suppl 4):46-53. Review. Czech.

PMID:
27846720
18.

Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.

Duan P, Fan L, Gao Q, Silwal BM, Ren M, Shen Y, Qu W.

Curr Drug Targets. 2017;18(10):1171-1178. doi: 10.2174/1389450118666170329095807. Review.

PMID:
28443505
19.

Ovarian cancer: Novel molecular aspects for clinical assessment.

Palmirotta R, Silvestris E, D'Oronzo S, Cardascia A, Silvestris F.

Crit Rev Oncol Hematol. 2017 Sep;117:12-29. doi: 10.1016/j.critrevonc.2017.06.007. Epub 2017 Jun 17. Review.

PMID:
28807232
20.

Front-line therapy of advanced ovarian cancer: new approaches.

Ledermann JA.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii46-viii50. doi: 10.1093/annonc/mdx452. Review.

PMID:
29232475

Supplemental Content

Support Center